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Abstract: The treatment of urinary tract infections (UTIs) continues to evolve as common 
uropathogens increasingly become resistant to previously active antimicrobial agents. In   addition, 
bacterial isolates, which were once considered to be either colonizers or contaminants, have 
emerged as true pathogens, likely related to the more complex array of settings where health 
care is now delivered. Even though the reliability of many antimicrobial agents has become 
less predictable, the fluoroquinolone group of agents has remained a frequent, if not the most 
often prescribed, antimicrobial therapy for almost all types of UTIs. Levofloxacin has taken its 
position at the top of the list as one of the most regularly administered fluoroquinolone agents 
given to patients with a suspected or proven UTI. The authors review the clinical experience 
of the use of levofloxacin over the past decade and suggest that the use of levofloxacin for the 
treatment of UTIs, although still fairly dependable, is perhaps not the best use of this important 
antimicrobial agent.
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Introduction
More than a decade has passed since levofloxacin was introduced as one of the newer 
fluoroquinolone antimicrobial agents. Exhibiting greater activity against Gram-positive 
cocci than its predecessors in the fluoroquinolone class, levofloxacin quickly emerged 
as a mainstay option for the treatment of community-acquired respiratory tract infec-
tion, where Streptococcus pneumoniae is an important pathogen. Successful clinical 
trials pitting levofloxacin against already approved antimicrobial agents for the treat-
ment of a variety of urinary tract infections (UTIs), along with the potential for shorter 
treatment courses with a drug administered once daily, proved to be two major factors 
leading to the very frequent prescribing of this medication for UTIs. As levofloxacin 
has not proven superior to alternative antimicrobial agents when treating UTIs caused 
by susceptible pathogens, the question of whether or not this is the best use for this 
valuable drug can be posed, particularly when less-expensive options are available. 
This comprehensive review of the utilization of levofloxacin for the treatment of UTIs 
is intended to help the prescriber make this decision.
UTIs are often classified, based on anatomic location, as either lower (cystitis) or 
upper (pyelonephritis, perinephric abscess), and as either complicated or   uncomplicated, 
based on the host comorbidities as well as on neurological or structural   abnormalities.1 
In general, except when encountered in a premenopausal, nonpregnant woman with no 
known anatomic urologic abnormality, most UTIs are felt to be complicated   infections, 
and the etiologic microorganisms responsible for these infections are more likely to 
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have resistance to at least one or more of the   commonly 
used antimicrobial agents for treating UTIs.2,3 Another 
epidemiologic feature divides UTIs into two main groups: 
catheter-associated UTIs (CA-UTIs), which are almost 
always nosocomially related, and non-catheter-associated 
UTIs, which are most often community acquired.
Community-acquired UTIs account for more than 
7   million office visits and 1 million hospitalizations annu-
ally in the United States (US), making them one of the most 
common recognized infections dealt with in clinical practice. 
In females, the incidence of UTIs increases with the onset of 
sexual activity, frequently in the adolescent years.4 Although 
UTIs are not uncommon in males during the first year of 
life, and are usually associated with urologic abnormalities, 
thereafter men under the age of 50 years rarely suffer from 
a UTI. The National Health and Nutrition Examination 
  Survey, which used a survey with a self-reporting UTI history, 
reported the annual incidence of UTI in the US for women 
aged 18 years and older was 12.6%, whereas for men it was 
just 3%.5 An estimated 1 million cases of nosocomial UTI 
are diagnosed in the US annually, and most are related to 
indwelling urinary catheters. In fact, a CA-UTI is the most 
prevalent nosocomial infection, accounting for approximately 
40% of all hospital-associated infections. However, many of 
these CA-UTIs are in reality nothing more than the unavoid-
able bacteriuria associated with having an indwelling bladder 
catheter, rather than real symptomatic infections.
Definitions and diagnosis of UTIs
The diagnosis of a UTI is based on a combination of clini-
cal signs and symptoms localizing the infectious process to 
either the lower (dysuria, frequency, and urgency) or upper 
urinary tract (flank pain and fever with or without lower uri-
nary tract symptoms), along with the finding of significant 
bacteriuria and pyuria (the presence of bacteria and pus in 
the urine, respectively). These criteria may not strictly apply 
to CA-UTIs, where much of the literature fails to distin-
guish between symptomatic and asymptomatic bacteriuria. 
Bacteriuria is best quantified by obtaining a urine specimen 
for culture from a fresh voided sample or via sterile urethral 
catheterization. Normally, urine in the bladder is sterile. 
However, urine specimens are often contaminated during 
the collection process. By quantitating bacteria in midstream 
clean-voided urine, it becomes possible to separate contami-
nation from a true UTI. The number of bacteria isolated in 
these cultures defines the term “significant bacteriuria.” 
Voided urine usually contains 105 bacteria/mL in patients with 
infection. However, about one-third of young women with 
symptomatic lower UTIs have fewer than 105 bacteria/mL 
of urine, prompting a consensus definition of cystitis as 103 
colony-forming units (CFU)/mL or more of a uropathogen 
and, for pyelonephritis, 104 CFU/mL or more.6 Bacteriuria is 
not an uncommon finding in otherwise asymptomatic patients 
(particularly elderly women), and as such it has been assigned 
the term “asymptomatic bacteriuria.” Although the presence 
of bacteria in the urine increases the risk of a symptomatic 
UTI, with the exception of pregnant women or those about 
to undergo an invasive urologic procedure, it generally does 
not need to be looked for or treated.7
Additional to the entrance of bacteria into the bladder 
via an indwelling urinary catheter, the routes by which 
these microorganisms invade and spread within the urinary 
tract include the ascending, hematogenous, and lymphatic 
pathways. The ascending route of infection is the most com-
mon and more than 95% of UTIs involve a single bacterial 
species, the majority of which are Gram-negative aerobic 
bacilli. Uropathogenic Escherichia coli, a pathogen distinct 
from that which generally colonizes the gastrointestinal 
tract, is the predominant strain leading to 75%–95% of 
UTIs in otherwise healthy young women.8 Surface adhesins, 
as well as other attachment organelles unique to E. coli 
and other urinary pathogens, enable these microorganisms 
to adhere to epithelial cell membranes, thus promoting 
colonization of the perineum, vagina, and urethral area 
with bacteria normally found in the colon. Certain activities 
such as sexual intercourse are known to help these colo-
nized bacteria ascend into the bladder, and at times into 
the kidney. The less common urinary pathogens include 
other members of the Enterobacteriaceae family, strepto-
cocci (especially group B beta-hemolytic   streptococci), 
enterococcal species, staphylococcal species (most often 
Staphylococcus   saprophyticus and Staphylococcus aureus) 
and Candida species. UTIs occurring in hospitals and 
long-term care   facilities frequently involve a more   varied 
group of   organisms that may include various species of 
Proteus, Klebsiella,  Enterobacter, Providencia, Morganella, 
  Citrobacter, Serratia, and Pseudomonas, as well as other 
uncommon bacterial organisms.9 While, the isolation of 
S. aureus from the urine should suggest the possibility of 
a hematogenous derived process, it may also be related to 
instrumentation and indwelling urinary catheters.
Factors that need be taken into consideration when 
choosing an antimicrobial agent to treat a UTI include (1) 
the anatomic location of the infection (ie, upper versus lower 
urinary tract or prostate); (2) complicated versus uncom-
plicated infection; and (3) community versus nosocomial 
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acquisition of infection. In addition, local patterns of   bacterial 
resistance, cost, patient compliance and allergy history must 
be taken into account.10 Table 1 provides information defin-
ing the various types of UTIs, the usual microorganisms 
encountered in these infections, and consensus antimicrobial 
agent recommendations. For over a decade of use and for 
every form of UTI, levofloxacin has had an important role 
in treating these infections.
Levofloxacin
Currently available fluoroquinolone antibiotics that are 
approved by the US Food and Drug Administration (FDA) 
for the treatment of UTIs (cystitis, prostatitis, complicated 
UTIs, and acute pyelonephritis) include ciprofloxacin, 
norfloxacin, ofloxacin, and levofloxacin. First patented in 
1987 and placed into initial clinical use in Japan in 1993, 
levofloxacin received subsequent FDA approval in the US for 
the treatment of severe and life-threatening bacterial infec-
tions in 1996. Primarily considered to be an antimicrobial 
agent best suited for the treatment of various respiratory 
tract infections caused by susceptible bacterial organisms, 
levofloxacin has also gained approval for use in treating skin 
and skin-structure infections as well as for postexposure 
treatment of inhalation anthrax.11 Moreover, based upon 
evidence resulting from various clinical trials, levofloxacin 
has proved effective for treating various forms of UTIs using 
different doses and durations of treatment in diverse patient 
populations. It is unique in that it has an approved indication 
for short-course regimens (5 days) for complicated UTIs and 
pyelonephritis, thus making it one of today’s most frequently 
prescribed anti-infective medications for this indication. In 
fact, levofloxacin ranked nineteenth in world sales of pre-
scribed drugs in the year 2007 and was the most frequently 
prescribed fluoroquinolone drug.
The first antimicrobial agent in the quinolone class, 
nalidixic acid, was derived from the antimalarial drug 
chloroquine.12 The evolution of these synthetic quinolone 
antimicrobial agents involves side-chain substitutions and 
nuclear manipulations. Involving the common quinolone 
dual-ring structure, these modifications result in improve-
ments in the spectrum and potency of antimicrobial activity 
and in superior bioavailability. The addition of a fluorine 
atom at position C-6 of the parent compounds (nalidixic acid 
and cinoxacin) gave rise to the original fluoroquinolones, 
commonly referred to as second-generation quinolones.13 As 
a group, these second-generation agents offer improved cov-
erage against Gram-negative bacteria along with moderately 
enhanced Gram-positive antibacterial activity.
Marketed under the brand names LEVAQUIN 
  (Ortho-McNeil-Janssen Pharmaceuticals, Inc, Raritan, NJ) 
and Tavanic (Sanofi-Aventis, Paris, France), the chemical 
name for levofloxacin is (-)-(S)-9-fluoro-2,3-dihydro-3-
methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-
de]-1,4-benzoxazine-6-carboxylic acid hemihydrate. The 
levofloxacin compound is the L-isomer, or S-enantiomer, of 
the two stereoisomeric racemic drug substance ofloxacin. 
Being the more potent of the two ofloxacin stereoisomers, 
levofloxacin exhibits twice the in vitro potency of ofloxacin.14 
The mechanism of action of levofloxacin and other fluoro-
quinolone antimicrobials involves inhibition of bacterial 
topoisomerase IV and DNA gyrase (both of which are type II 
topoisomerases), enzymes required for DNA replication, 
transcription, repair, and recombination.15 For most Gram-
negative bacteria, DNA gyrase is the primary quinolone 
target; for many Gram-positive bacteria, topoisomerase IV 
is the primary target, with gyrase being the secondary target. 
These patterns appear to result from the relative sensitivities 
of these two topoisomerases to a given quinolone, with the 
more sensitive of the two enzymes defining the target of a 
particular quinolone and eventually attributing to the activ-
ity and potency of each drug against Gram-negative and/
or Gram-positive bacterial microorganisms.16 In any event, 
the ultimate outcome of quinolone-driven rapid inhibition 
of bacterial DNA synthesis is rapid bacterial cell death, 
which takes place even among bacteria in stationary phases 
of growth.
Antimicrobial spectrum of activity
Levofloxacin, like all current fluoroquinolone agents, is 
most active against aerobic Gram-negative bacilli, particu-
larly members of the Enterobacteriaceae family. Although 
ciprofloxacin remains the most potent of the available fluo-
roquinolones against Gram-negative bacteria, levofloxacin 
is the only other marketed drug belonging to this class of 
antimicrobial agents with sufficient activity for use against 
susceptible strains of Pseudomonas aeruginosa. A distinct 
advantage of levofloxacin and other advanced-generation 
fluoroquinolones over their predecessors is their enhanced 
antimicrobial activity against certain Gram-positive organ-
isms, especially species of streptococci.17 However, in vitro 
susceptibility data may not translate into successful in 
vivo outcomes, owing to the fact that drug concentrations 
necessary for effective antimicrobial action at the specific 
site of infection may not be achievable when interpreted in 
relation to peak drug concentrations in serum. Nevertheless, 
even though activity in vitro is diminished in the presence 
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of urine (reduced by pH values below 7), except for those 
  fluoroquinolones that are largely excreted by nonrenal 
mechanisms (ie, moxifloxacin), levofloxacin, as well as 
others, demonstrates drug concentrations in urine that are 
much higher than in serum. Table 2 lists the better-known 
Gram-negative and Gram-positive uropathogens against 
which levofloxacin has demonstrated sufficient antimicrobial 
activity in controlled clinical trials (approved indications 
based on in vivo data), and Table 3 lists other bacterial 
species against which antimicrobial activity data have been 
documented in studies conducted in vitro only. Although 
adequate in vitro activity suggests that levofloxacin may 
be effective against these potential UTI bacterial isolates 
in clinical practice, this fact has not been established in 
well-controlled clinical trials. Combining levofloxacin with 
a beta-lactam or aminoglycoside antimicrobial agent has 
not proven to be synergistic. When used together with one 
of these agents, the bactericidal activity achieved is at best 
additive, but generally indifferent, making such practice 
unwarranted when using levofloxacin to treat UTIs.17
Pharmacokinetics and pharmacodynamics
The favorable pharmacokinetic properties of the later-
generation fluoroquinolones, in part, have encouraged their 
widespread use.18 Among these agents, levofloxacin has one 
of the best pharmacokinetic profiles (Table 4). Its bioavail-
ability of 99%, rapid absorption (1–3 hours), and good 
tissue penetration (volume of distribution 102 L), allow for 
dependable treatment of UTIs and many other clinical infec-
tion syndromes with the oral administration of levofloxacin. 
Following the oral or intravenous administration of a 500 mg 
dose, a maximum concentration of 5.7 µg is reached, 60% of 
which is free or active owing to low serum protein binding 
(40%). The ingestion of food may delay the time it takes for 
levofloxacin to attain its maximal serum concentration, but 
meals do not hinder the extent of levofloxacin absorption. 
Approximately 77% of levofloxacin is excreted as unchanged 
drug via renal elimination and this occurs at a clearance of 
116 mL/min. Levofloxacin has an elimination half-life of 
6–8 hours, allowing for once-daily dosing of this antimicro-
bial agent. Adjustments in levofloxacin dosing are required in 
the setting of renal insufficiency. It is recommended that the 
usual normal doses of 250–750 mg every 24 hours should be 
lowered to one-half this amount given every 24 hours if the 
glomerular filtration rate (GFR) is between 10 and 50 mL/min 
and extended to every 48 hours if the GFR falls below 10 mL/
min.19 Neither hemo- nor peritoneal dialysis remove levo-
floxacin to any significant degree, eliminating the need for 
Table 2 Levofloxacin antimicrobial activity in vitro and in vivo 
for urinary pathogens (clinical studies described in manufacturer’s 
Indications and Usage)12
Aerobic Gram-negative microorganisms
Enterobacter cloacae 
Escherichia coli 
Klebsiella pneumoniae 
Proteus mirabilis 
Pseudomonas aeruginosa
Aerobic Gram-positive microorganisms
Enterococcus faecalis (many strains are only moderately susceptible) 
Staphylococcus aureus (methicillin-susceptible strains) 
Staphylococcus epidermidis (methicillin-susceptible strains) 
Staphylococcus saprophyticus
Note: Approved indications based on in vivo data.
Table 3 Levofloxacin antimicrobial activity in vitro for urinary 
pathogens (clinical significance not established in adequate, well-
controlled trials)
Aerobic Gram-negative microorganisms
Acinetobacter baumannii 
Acinetobacter lwoffii 
Citrobacter freundii 
Citrobacter koseri 
Enterobacter aerogenes 
Enterobacter sakazakii 
Klebsiella oxytoca 
Morganella morganii 
Pantoea agglomerans 
Proteus vulgaris 
Providencia rettgeri 
Providencia stuartii 
Pseudomonas fluorescens
Aerobic Gram-positive microorganisms
Staphylococcus haemolyticus 
Streptococcus agalactiae (beta-hemolytic group B) 
Viridans streptococci
Table 4 Levofloxacin pharmacokinetic/pharmacodynamic proper-
ties in serum (single oral dose)
Property Dose (mg)
250 500 750
Bioavailability (%) 99 99 99
Protein binding (%) 40 40 40
Tmax (h) 1.6 1.6 1.6
Cmax (µg/mL) 2.8 5.1 9.3
Vd (L) ND 102 83
Half-life (h) 7.3 6.3 7.5
AUC (µg.h/mL) 27 50 101
Renal excretion (%) 77 77 77
Renal clearance (avg mL/min) 142 103 ND
Abbreviations:  AUC,  area  under  the  concentration-time  curve;  avg,  average; 
Cmax,  maximum  concentration;  ND,  not  determined;  Tmax,  time  to  maximum 
concentration; Vd, volume of distribution.
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any further alterations in dosing in patients undergoing these 
procedures.20 Fewer data are available on the effects of hepatic 
insufficiency on quinolone half-life, but in general no specific 
dosage adjustment is recommended when using levofloxacin 
in patients with Child classes A and B cirrhosis.
On the whole, interactions with other drugs are of 
minimal concern when using levofloxacin. However, the 
formation of a cation-quinolone complex is known to occur 
when levofloxacin is coadministered orally with antacids that 
contain the di- and trivalent cations aluminum, magnesium, 
zinc, or calcium. Absorption of these complexes is difficult, 
markedly reducing the bioavailability of levofloxacin as 
well as other orally administered fluoroquinolone agents 
when given together with antacids.21 Consequently, stag-
gering the oral dosing of levofloxacin is suggested if given 
to a patient who is also receiving any product containing 
these cations. In general, it is recommended to administer 
the levofloxacin 2 hours before or 4 hours after the offend-
ing agent. Unlike some of its predecessor quinolone agents, 
levofloxacin has little or no effect on slowing the metabolism 
of the methylxanthines theophylline and caffeine, owing to 
its minimal inhibitory effect on the hepatic cytochrome P450 
isoenzyme 1A2 (CYP1A2).22 Levofloxacin may uncom-
monly promote the anticoagulation effect of warfarin but has 
never convincingly been associated with excessive bleeding. 
Nonsteroidal anti-inflammatory drugs may potentiate the 
central nervous system stimulant effects of certain fluoro-
quinolones, particularly levofloxacin, and possibly lead to 
seizure activity, requiring a warning to patients receiving 
both medications.23
Optimizing the bactericidal activity of any antimicrobial 
agent is critical in order to best achieve the main goal of their 
use – that is, to eradicate the causative organism(s) from the 
site of infection, thereby helping to bring about a successful 
clinical outcome. Ideally, the choice of antimicrobial agent 
would also effectively limit the development and selection 
of bacterial resistance to a single drug or to others within 
or outside the chosen antibiotic class. Therefore, using the 
minimal inhibitory concentration (MIC), either predicted 
or measured, of a bacterial isolate as the single criterion for 
selecting an agent fails to fully take into consideration the 
mechanism of antimicrobial killing for a particular drug. The 
pharmacodynamic parameters typically used to predict the 
antimicrobial efficacy of levofloxacin, as for all of the fluoro-
quinolones, are the ratios of the area under the concentration-
time curve to the MIC (AUC/MIC) and peak concentration 
to the MIC (Cmax/MIC).24 Since the fluoroquinolones fall into 
this category of concentration-dependent killers, capitalizing 
on these pharmacodynamic parameters not only improves the 
likelihood of bacterial eradication but also helps to prevent 
the development of resistance to fluoroquinolone agents, 
a relatively new concept known as the mutant prevention 
concentration effect.25 Although a threshold value of AUC/
MIC likely varies by disease state and target organism, 
when treating infectious processes involving aerobic Gram-
negative bacilli, an AUC/MIC ratio greater than 125 has 
been associated with a superior probability of clinical and 
microbiologic cure.26 By modeling the pharmacodynamic 
data from trials using levofloxacin, it has been determined 
that a Cmax/MIC ratio of at least 12.2 is necessary in order 
to achieve favorable outcomes.27   Retrospective analysis of 
pooled clinical trials suggested that the AUC/MIC ratio was 
also a relatively strong predictor of bacterial resistance, which 
was found to occur significantly more often when this ratio 
fell below 100.26,27
Achieving these desired pharmacodynamic parameters 
is generally not an obstacle when using levofloxacin, par-
ticularly when treating UTIs, where the concentration of the 
drug greatly exceeds that of serum. The MICs of most Enter-
obacteriaceae for levofloxacin are significantly low, so that 
at a dose of 500 mg every 24 hours, the AUC of levofloxacin 
in serum (total drug) that approximates 48 mg/h/L yields an 
AUC/MIC ratio that is magnitudes higher than the desired 
target value of 125. Treating some isolates of P . aeruginosa 
with levofloxacin may prove to be more challenging, because 
of higher MICs against this organism. Nevertheless, the 
readily achievable drug levels in urine helps to overcome 
this problem.
Clinical efficacy
More than 600 million persons worldwide have been pre-
scribed levofloxacin, mostly for the treatment of UTIs and 
respiratory tract infections.28 Approval for its use in treating 
UTIs in the US dates back to 1998. Currently, levofloxacin 
is indicated for acute, mild to moderate uncomplicated UTIs 
(250 mg/day for 3 days), complicated UTIs or acute pyelo-
nephritis (both 250 mg/day for 10 days and 750 mg/day for 
5 days), and chronic bacterial prostatitis (500 mg/day for 
28 days). The initial safety and efficacy trial comparing levo-
floxacin 250 mg orally once daily with ciprofloxacin 500 mg 
orally twice daily for 10 days was conducted in a random-
ized, double-blind, multicenter fashion in the US between 
1993 and 1995.29,30 Microbiologic efficacy was measured 
by bacteriologic eradication of the baseline organism(s) at 
1–12 days post therapy in patients with a pathogen identified 
at entry. In the modified intent-to-treat (mITT) population, 
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which included all patients with a documented pathogen at 
baseline, overall bacteriologic eradication at the test-of-cure 
visit occurred in 83% and 84% in the levofloxacin and cip-
rofloxacin arms, respectively, in patients with complicated 
UTIs or acute pyelonephritis. In the microbiologically 
evaluable (ME) population (this did not include patients with 
missing response who were counted as failures in the mITT 
arm), the results were 92% for levofloxacin versus 93% for 
ciprofloxacin.
Levofloxacin is unique among the quinolone class of drugs 
in having the only indication for short-course regimens (5 days) 
for complicated UTIs and pyelonephritis. The observed non-
inferiority of a shorter treatment course comes from a recent 
randomized, double-blind trial that compared levofloxacin 
750 mg taken intravenously or orally once daily for 5 days 
with ciprofloxacin 400 mg taken intravenously or 500 mg taken 
orally twice daily for 10 days.31 Inclusion criteria consisted 
of the demonstration of greater than 105 CFUs of one or two 
uropathogens; two or more signs or symptoms including fever, 
leukocytosis, or costovertebral angle tenderness; and symp-
toms of a UTI. A complicated UTI was defined as having at 
least one complicating factor such as (1) a neurogenic bladder 
or urinary retention; (2) partial obstruction; or (3) intermittent 
catheterization. The majority of the isolated Gram-negative 
bacilli pathogens were E. coli, while enterococci accounted for 
about one-half of the infrequently involved Gram-positive bac-
terial organisms. The overall bacteriologic cure rates were 75% 
versus 75% for levofloxacin and ciprofloxacin, respectively, in 
the mITT population and 86% versus 89% for levofloxacin and 
ciprofloxacin, respectively, in those patients considered ME 
by meeting protocol-specific evaluability criteria. Bacterio-
logic cure rates in both populations were numerically higher 
in those diagnosed with acute pyelonephritis compared with 
complicated UTI, probably related to the lack of confounding 
complicating factors in the former. No significant difference 
was observed in relation to the specific pathogen isolated at 
baseline either within the levofloxacin-treated group or when 
compared with the ciprofloxacin arm. Not surprisingly, in the 
subgroup of patients who had a urinary catheter, eradication 
of the baseline bacteria occurred less frequently than in those 
who did not. However, an interesting observation was that a 
significantly greater proportion of patients treated with levo-
floxacin achieved microbiologic eradication compared with 
ciprofloxacin recipients with catheters. In spite of this find-
ing, the rate of clinical success was not significantly different 
between levofloxacin and ciprofloxacin patients even in this 
group of catheterized individuals when keeping to the observed 
outcome in the overall population of treated patients.
Coinciding with the proliferation of trimethoprim/ 
sulfamethoxazole (TMP/SMX)-resistant E. coli, fluoroqui-
nolones were advocated for recommendation as the first-line 
empirical therapy of choice for acute uncomplicated cystitis,32 
especially when local resistance to TMP/SMX exceeded 
10%–20%. Over the years, levofloxacin has assumed the 
position as one of the most often, if not the most often, 
prescribed antimicrobial agents for this condition. How-
ever, contrary to the early 2000s, when levofloxacin was 
proposed for infections as simple as uncomplicated cystitis, 
the most recent Infectious Diseases Society of America 
guidelines have relegated levofloxacin, together with other 
fluoroquinolone agents, to alternative status, in part because 
of increasing fluoroquinolone local resistance of bacterial 
pathogens in both cystitis and acute pyelonephritis, along 
with the perceived need to reserve these important drugs for 
more serious infections such as pyelonephritis.
Chronic bacterial prostatitis, which involves the persis-
tence of bacteria in the male lower urinary tract, is often an 
arduous condition to resolve. Factors that may influence the 
risk of antimicrobial treatment failure include suboptimal 
diffusion of many antimicrobial agents into the prostatic 
parenchyma, alterations in prostatic pH level associated with 
infection, and calculi that can act as foci for chronic bacte-
rial infection. The fluoroquinolone agents are considered the 
preferred drugs for treatment of this condition, with cure rates 
of 70% or more in some series.33 In the randomized, double-
blind, multicenter trial comparing levofloxacin 500 mg with 
ciprofloxacin 500 mg, both once daily for a total of 28 days,34 
the microbiologic eradication rates at 5–18 days after comple-
tion of therapy were equivalent: 75% in the levofloxacin 
group and 76% in the ciprofloxacin group. Moreover, the 
eradication rates in both arms were similar, regardless of 
whether or not Gram-negative bacilli or Gram-positive patho-
gens were involved. Clinical success, defined as cure plus 
improvement with no need for further antimicrobial therapy 
5–18 days after completion of treatment, and clinical long-
term success (24–45 days after completion of treatment) were 
75% and 66%, respectively, for levofloxacin-treated patients 
and 72% and 77%, respectively, for ciprofloxacin-treated 
patients. Although not proven in clinical trial, levofloxacin 
would appear to have a potential treatment advantage based 
upon the knowledge that in one study volunteers receiv-
ing a single dose of levofloxacin 250 mg were measured 
to have both plasma and prostatic fluid concentrations 
of drug significantly higher than those who were given a 
single dose of ciprofloxacin 250 mg.35 Interestingly, a large, 
Canadian, randomized, placebo-controlled, multicenter trial 
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aimed at evaluating the safety and efficacy of 6 weeks of 
  levofloxacin therapy (500 mg once daily) compared with 
placebo in chronic prostatitis/chronic pelvic pain syndrome 
resulted in symptom improvement that was not significantly 
different from that with placebo at the end of treatment or 
follow-up.38 These results likely relate to the fact that only 
approximately 5% of men with chronic prostatitis/chronic 
pelvic pain syndrome have definite bacterial infection,37 and 
therefore giving a drug aimed at the eradication of bacteria 
would intuitively seem to offer little, if any, advantage over 
other non-antimicrobial therapies.
All of the major clinical studies evaluating levofloxacin for 
the treatment of various UTIs used another fluoroquinolone 
drug as the comparator. Without exception, levofloxacin 
produced similar microbiologic and clinical response rates, 
with the major distinction being that levofloxacin performed 
equally well when only given for a 5-day treatment period. 
To date, no data are available regarding a comparison of 
levofloxacin with other classes of antimicrobial drugs. None-
theless, recognizing the lack of direct comparisons, similar 
microbiologic success rates ranging from 71% to 91% have 
been reported in trials using beta-lactams, monobactams, 
carbapenems, and aminoglycosides.38 However, a paren-
teral route of administration was necessary with these other 
agents.
Resistance
The huge expansion in the use of fluoroquinolone antimi-
crobial agents for a variety of infections, including condi-
tions with proven indications as well as those lacking trial 
study data, has correlated with the increasing development 
of resistance. This disturbing phenomenon has occurred 
on both ecologic and individual levels.39 The emergence 
of fluoroquinolone-resistant strains of Enterobacteriaceae 
among in- and outpatients in the US and around the world 
has outpaced that observed with Gram-positive pathogens, 
except in Asia, where S. pneumoniae-resistance rates are now 
greater than 13%.39 Historically, resistance to fluoroquino-
lones has been determined to be caused by either mutation 
of the target enzymes or reduction of intracellular drug 
concentration via the action of efflux pumps or alterations 
in porin channels through which the drug enters the bacte-
rial cell. Chromosomal point mutations due to amino acid 
substitutions in the corresponding genes in DNA gyrase and 
topoisomerase IV at a site corresponding to a region on the 
DNA-binding surface of the enzyme effect drug affinity at the 
DNA-enzyme complex.40 A single mutation in one of these 
genes is often sufficient to significantly reduce   sensitivity to 
the fluoroquinolones. In a stepwise fashion, those bacteria 
that are able to survive the bactericidal effect of the drug 
accumulate additional mutations, subsequently resulting 
in a further increase in resistance to the drug. The primary 
target enzyme for a bacterial strain (eg, DNA gyrase in Gram-
negative bacilli and topoisomerase IV for Gram-positive 
organisms) is most often the first affected by mutation.
A second mechanism of resistance involves the overex-
pression of efflux pumps in some bacteria. Generally, these 
intrinsic components of the bacterial cell membrane expel 
waste and other harmful substances from the organism. The 
efflux pump allows for survival of the bacteria in the presence 
of the fluoroquinolone agent by actively expelling the drug 
across the cell membrane, thereby diminishing the intracel-
lular concentration of drug to sublethal levels. The action of 
the efflux pump is dependent on the degree to which the drug 
binds to the bacterial efflux protein required for exportation. 
Certain fluoroquinolone agents (eg, moxifloxacin) are less 
susceptible to this mechanism of resistance, owing to their 
bulky molecular side chains. Since efflux pumps tend to 
export a number of different classes of antimicrobial agents 
in addition to the fluoroquinolones, multidrug-resistant 
organisms may be selected out.41 In general, efflux pumps 
are associated with lower levels of nonsusceptibility to fluo-
roquinolones than target enzyme mutations.
More recently, transferable fluoroquinolone resistance 
has been linked to plasmid-mediated mechanisms in many 
clinical isolates of Enterobacteriaceae from wide geographic 
areas.42 It appears that the plasmid-encoded genes, named 
qnr, produce proteins that protect DNA gyrase and topoi-
somerase IV from inhibition by the fluoroquinolone drug. 
Although, the acquisition of these transferable genes may not 
be sufficient to confer clinical resistance to fluoroquinolones, 
they are thought to facilitate bacterial survival, and thus aid in 
the selection of chromosomal mutations.40 On the whole, in 
regard to Gram-negative bacilli uropathogens, any organism 
that is found to be resistant to ciprofloxacin by the Clinical 
and Laboratory Standards Institute will likely demonstrate a 
similar or higher level of resistance to levofloxacin.
Surveillance of urinary bacterial isolates collected 
between 1989 and 1997 found that fluoroquinolone resis-
tance in E. coli was virtually nonexistent during this period 
of time.43 Unfortunately, extensive hospital-wide use has 
correlated with the rising resistance now observed, particu-
larly among E. coli, Klebsiella pneumoniae, and Proteus 
mirabilis. In fact, in one large urban teaching hospital in 
South Florida, about 50% of the E. coli strains submitted 
to the microbiology laboratory for susceptibility testing 
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were found to be   resistant to levofloxacin, according to their 
2010 antibiogram (L Bush, personal communication). The 
newly and worrisome increment in extended-spectrum beta-
lactamase-producing E. coli and other Gram-negative bacilli 
plays a significant role in resistance to fluoroquinolones. The 
vast majority of these strains carry with them resistant deter-
minants to all available agents in the fluoroquinolone class of 
antimicrobials.44 In a carbapenem susceptibility test informa-
tion collection program performed in 15 US medical centers 
in 2007, resistance to fluoroquinolone agents was detected 
in 29%, 21%, 201%, and 20% of E. coli, Klebsiella species, 
P . mirabilis, and P . aeruginosa, respectively.45 Resistance to 
Enterobacteriaceae as well as nonfermenting Gram-negative 
bacilli is not exclusive to health care-associated infections. 
A North American Urinary Tract Infection Collaborative 
Alliance multicenter surveillance study carried out in the 
US and Canada between 2003 and 2004 determined that 
resistance to levofloxacin and ciprofloxacin was about 6%.46 
Contributing factors to the expansion of fluoroquinolone 
resistance now recognized in the outpatient setting include, 
but are not limited to, (1) their frequent use in treating respi-
ratory tract infections leading to colonization of the fecal 
flora with resistant E. coli; (2) prophylactic use in oncology 
patients during periods of neutropenia; and (3) the heavily 
criticized utilization of quinolone agents in the poultry and 
beef industries, resulting in the possibility of contaminating 
the food supply with resistant E. coli. Although levofloxacin 
has been found to present the lowest frequency of resistance 
mutations at normal plasma concentrations,47 only the judi-
cial and appropriate use of this, as well as other marketed 
fluoroquinolone agents, will curtail the ever-growing crisis 
of resistance to our limited armamentarium of effective 
antimicrobial agents.
Safety, tolerability, and adverse events
When considering the significant amount of doses of levo-
floxacin administered over more than a decade’s worth of 
prescribing, it can be confidently stated that this antimicrobial 
agent has proven to be safe and well tolerated and to have 
no higher frequency of adverse events than the comparator 
fluoroquinolones used in study trials or clinical practice. 
Overall, several pre- and post-marketing trials with levo-
floxacin have identified the overall incidence of any grade 
adverse reaction to be from 2% to 10%.18 When reviewing 
a total of 7537 treated patients from 29 phase 3 clinical 
trials, the overall incidence and type of adverse reactions 
was independent of the dose of levofloxacin administered. 
The most frequently reported adverse reactions ($1%) are 
listed in Table 5. In total, 4% of the enrollees discontinued 
levofloxacin because of an adverse drug reaction, most com-
monly gastrointestinal complaints or headache.
Partly as a result of many of its predecessor or contempo-
rary fluoroquinolone agents (eg, temafloxacin, lomefloxacin, 
sparfloxacin, gatifloxacin, grepafloxacin, and trovafloxacin) 
being removed from clinical use for reasons of severe toxicity 
(including hepatotoxicity, hemolytic anemia, photosensitiv-
ity, dysglycemia, and increased risk of cardiac arrhythmia), 
levofloxacin comes with package insert warnings mentioning 
the rare possibility of these harmful events occurring while 
on medication. As with all other antimicrobials, the most fre-
quently reported side effects attributed to levofloxacin use are 
gastrointestinal symptoms, including anorexia, nausea, vomit-
ing, abdominal discomfort, and diarrhea. Specific molecular 
structural components on the fluoroquinolone compound, such 
as side-chain or ring substitutions, are known to be related 
to certain side effects or toxicities. However, no particular 
structural element has been determined to correlate with 
gastrointestinal toxicity.48 Among the newer fluoroquinolone 
agents, levofloxacin appears to produce the lowest frequency 
of non-gastrointestinal side effects. Central nervous system 
side effects are reported to take place in anywhere from 1% 
to 11% of patients prescribed fluoroquinolones. Second only 
to gastrointestinal complaints, these events can manifest as 
mild to severe headache, dizziness, confusion, insomnia, and 
mood swings. Seizures may also occur and are hypothesized 
to be connected to the drug’s interaction with the inhibitory 
neurotransmitter gamma-aminobutyric acid or its brain-tissue 
receptor.49 The development of a rash while taking levofloxa-
cin, felt to be an allergic reaction to the medication, occurs 
much less frequently than with   beta-lactam or sulfa-based 
Table 5 Levofloxacin clinical trial adverse reactions ($1%)
Organ system and type % (N = 7537)
Gastrointestinal
  Nausea 7
  Diarrhea 5
  Constipation 3
  Dyspepsia 2
  Abdominal pain 2
  Vomiting 2
Central nervous system
  Headache 6
  Dizziness 3
Psychiatric
  Insomnia 4
Skin/tissue disorders
  Rash 2
  Pruritus 1
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antimicrobial agents. However, this cutaneous event must be 
distinguished from a phototoxicity reaction, which manifests 
as a severe sunburn in unprotected areas appearing within 
hours of exposure to ultraviolet light. Those fluoroquinolones 
(most have been removed from the market) that are multi-
fluorinated or that possess halogen atoms at position 8, of 
which levofloxacin is not, are known to increase phototoxicity. 
Levofloxacin has rarely been associated with anaphylactoid 
reactions (#1.2 cases per 100,000).39 A history of anaphylaxis 
to any fluoroquinolone drug should preclude the prescribing 
of levofloxacin, since substantial cross-reactivity exists among 
these agents. Over the years, levofloxacin has infrequently 
been implicated as a cause of nephro- or hepatotoxicity, the 
latter generally presenting as mild and reversible elevations 
in serum transaminases and alkaline phosphatase. Crystal-
luria and interstitial nephritis have been reported with the 
administration of levofloxacin.
Certain serious toxicities that have been reported to occur 
with levofloxacin use are unique to the fluoroquinolone 
family of antimicrobial agents. Tendinopathy, presenting as 
tendonitis or tendon rupture, mostly involving the   Achilles 
tendon but also other tendons of weight-bearing joints, has 
been reported in association with the earliest quinolone 
agents. In 2008, the FDA added a “black box” warning to all 
fluoroquinolone agents cautioning of this risk, which appears 
to be increased in certain populations, such as patients over 
60 years of age, those taking corticosteroid medications, and 
organ transplant recipients.50,51 Prolongation of the electrocar-
diogram QT interval leading to torsades de pointes and other 
ventricular arrhythmias is a serious toxicity that may occur 
while on a fluoroquinolone drug. By blocking the potassium 
channels, thereby delaying ventricular repolarization, these 
drugs may cause this potentially life-threatening event, par-
ticularly in certain patient populations at increased risk for 
developing cardiac arrhythmias. Persons who may be more 
prone to QT interval prolongation while on levofloxacin 
are those who have significant cardiac disease, electrolyte 
abnormalities (eg, hypokalemia, hypomagnesemia), and/or 
are receiving other drugs likely to prolong the QT interval 
(eg, class Ia or III antiarrhythmic). Levofloxacin and cipro-
floxacin appear to have lesser effects on QT interval prolonga-
tion than other drugs within their class.52 Contrary to some 
fluoroquinolones that have been noted to cause elevations 
in blood glucose levels (hyperglycemia), a slight increase in 
the risk for hypoglycemia has been linked to treatment with 
levofloxacin. The mode of action is believed to be an increase 
in pancreatic insulin secretion by inhibition of adenosine 
triphosphate-sensitive potassium channels in beta cells.53 
Levofloxacin, along with all other fluoroquinolone agents, 
has not been established as safe for use in pregnant women, 
and likewise should be avoided in nursing mothers. It is also 
not recommended for pediatric use.
The acceptance by patients of levofloxacin for treatment 
of UTIs and other indicated infections has been quite positive, 
as evidenced by the millions of prescriptions filled.   However, 
a notable exception to this is the severe condemning state-
ments posted by patients on websites such as WebMD (http://
www.webmd.com) and that of the Fluoroquinolone Toxic-
ity Research Foundation (http://www.fqresearch.org), the 
majority of which focus on tendinopathy issues and central 
nervous system events. Levofloxacin is also significantly 
more expensive than other fluoroquinolones that are now 
available in generic form and which have shown similar 
efficacy for the treatment of UTIs.
Conclusion
Since receiving FDA approval for the treatment of UTIs, 
levofloxacin has taken its place as a mainstay antimicrobial 
agent for management of this condition. Possessing excep-
tional pharmacokinetic and pharmacodynamic profiles, a 
broad spectrum of antimicrobial activity against most uro-
pathogens, and a safety record that has withstood the test of 
time, levofloxacin undoubtedly has played an important role 
in the treatment of UTIs and has earned its status as a “stan-
dard of care” drug for these infections. However, other than 
having a 5-day indication for the treatment of complicated 
UTI and acute pyelonephritis, and more activity against 
common Gram-positive organisms sometimes encountered 
in UTIs (although this is of questionable clinical benefit), 
levofloxacin has not proven superior to other drugs from 
either the fluoroquinolone or alternative classes of antimi-
crobial agents. Moreover, acknowledging that adverse drug 
reactions and toxicities attributed to fluoroquinolone use may 
vary in reported incidence, and in fact may prove lower with 
levofloxacin, patients prescribed levofloxacin for UTIs must 
still be warned of these potentially serious side effects.
Worrisome levels of fluoroquinolone resistance have 
developed as a consequence of the heavy use of levofloxacin 
and other drugs from this class. As pointed out in recent UTI 
treatment guideline papers,32 resistance in Gram-negative 
uropathogens jeopardizes the continued empirical use of 
levofloxacin for any form of UTI. Because of these concerns, 
as well as the significantly higher cost of treating a UTI with 
this medication, perhaps, except for specific circumstances, 
levofloxacin should be relegated to treatment of respiratory 
tract infections, a role it now seems better suited to.
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